Supersaturated Oxygen (SSO2) Therapy in STEMI Treatments

Published: 06 December 2021

  • Views:

    Views Icon 3426
  • Likes:

    Heart Icon 0

Overview

Full programme

  • Views:

    Views Icon 3426
  • Likes:

    Heart Icon 0

Overview

Despite advances in reperfusion with primary stenting, progress in STEMI outcomes has stalled over the past 20 years. With 90% of coronary blood flow in the capillaries, the answer might be in the microvasculature. TherOx SSO2 Therapy is the first FDA approved therapy shown to significantly reduce the infarct size in STEMI patients.

 

During this series of webinars on Supersaturated Oxygen (SSO2) Therapy, our faculty of renowned international experts will discuss and dissect the mechanisms and data around this promising new therapy for STEMI patients.

This webinar series is supported by

Key Objectives

  • Understand how SSO2 Therapy works
  • Hear about trends in STEMI treatment
  • Explore the role of microvascular obstruction and infarct size in outcomes
  • Understand the science behind SSO2 Therapy

Target Audience

This series is designed for the entire cardiology community:

  • Interventional Cardiologists
  • Cardiologists
  • Clinical Fellows and Trainees

Series overview

Part 1

Supersaturated Oxygen Therapy (SSO2): The Next Frontier in STEMI Treatment

Learn about the mechanism and data around SSO2 Therapy for STEMI patients with leading experts, Dr Gregg Stone and Dr Robert Kloner.

6 sessions

Part 2

SSO2 Therapy in STEMI to Reduce Infarct Size: A Conversation with Global Thought Leaders

Learn about this promising new therapy for STEMI patients and hear from global thought leaders, Dr Dan Burkhoff, Dr Steven Yakubov, Dr Andreas Schäfer and Dr Richard Schatz, about their experiences with it.

6 sessions

Faculty biographies